- NASDAQ: VXRT is set to complete a full week of daily gains with another rise on Friday.
- Vaxart Inc may emerge as a dark horse in the race to achieve a COVID-19 vaccine.
- The pharma firm's oral tablet solution would be more practical than any competing company.
Protection against coronavirus with just a pill? Vaxart Inc (NASDAQ: VXRT) is aiming for an easy-to-digest solution to the disease that is gripping the world. Another advantage of the pharma firm's immunization candidate is that it can be stored at room temperature – contrary to inoculations from Pfizer and Moderna, which require cold chain storage during most of their transport.
While also Inovio's immunization doses can survive in normal room temperatures – a fact pushing NASDAQ: INO higher – they require application via the skin. Vaxart's orally administered tablet has a substantial advantage over any competitor.
The South San Francisco-based company's "dark horse" status is due to its backward position in the race – it is still in preclinical trials with hamsters, rather than advanced phases such as the companies mentioned above. Nevertheless, the hamsters have shown the results the firm wanted to see – a potent immune response in animals receiving doses of the vaccine.
Moreover, the animals were exposed to COVID-19 and showed a considerable reduction in lung viral load. Those that hadn't been granted the doses suffered substantial weight loss and ruffled furs.
Can Vaxart eventually surpass competitors? With production, storage, and distribution issues, there will likely be more than one, two, or even a dozen winners. Moreover, if vaccines' impact lasts only one season or two years, the second generation of covid immunizations could have significant room for Vaxart's oral solution.
Vaxart Stock Forecast
NASDAQ: VXRT is changing hands at $5.94 on Friday's premarket trading, up from $5.91. While the increase is minimal, if sustained, it would be the fifth consecutive day of increases. A steady rise may provide confidence for CEO Andrei Floroiu and investors.
Shares have been fluctuating between a 52-week low of $0.27 to a 52-week high of $17.49. A more solid uptrend could imply a healthier increase with fewer drawdowns.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.